Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMN7SDE)

• Drug Name: Methyclothiazide Drug Info
• Synonyms: Aquaresen; Aquatensen; Duretic; Enduron; Enduronum; METHYLCLOTHIAZIDE; Methychlothiazide; Methyclothiazid; Methyclothiazidum;Methycyclothiazide; Methylchlorothiazide; Methylcyclothiazide; Meticlotiazida; Meticlotiazide; Naturon; Meticlotiazide [DCIT]; Ciba 7272-Su; Enduron (TN); Methyclothiazidum [INN-Latin]; Meticlotiazida [INN-Spanish]; Naturon (VAN); Methyclothiazide (JAN/USP/INN); Methyclothiazide [USAN:INN:BAN:JAN]; (+-)-6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-,1,1-dioxide; 2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxid;2H-1,2,4-Benzothiadiazine-7-sulfonamide, 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-, 1,1-dioxide; 6-Chloro-3-(chloromethyl)-2-methyl-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2, 4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulfonamide 1,1-dioxide; 6-Chloro-3-chloromethyl-2-methyl-7-sulfamyl-3,4-dihydro-1,2,4-benzothiadiazine 1,1-dioxide; 6-chloro-3-(chloromethyl)-2-methyl-1,1-dioxo-3,4-dihydro-1

Indication

Disease Entry	ICD 11	Status	REF
Edema	MG29	Approved	[1]
Hypertension	BA00-BA04	Approved	[1]

• Therapeutic Class: Antihypertensive Agents
• Cross-matching ID:
  PubChem CID: 4121
  ChEBI ID: CHEBI:6847
  CAS Number: CAS 135-07-9
  TTD Drug ID: DMN7SDE
  VARIDT Drug ID: DR01031
  ACDINA Drug ID: D00416

Molecule-Related Drug Atlas

Drug(s) Targeting Solute carrier family 12 member 1 (SLC12A1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Aldosterone	DM9S2JW	Hypertension	BA00-BA04	Approved	[3]
Potassium Chloride	DMMTAJC	Hypokalemia	5C77	Approved	[4]
Furosemide	DMMQ8ZG	Congestive heart failure	BD10	Approved	[5]
Bumetanide	DMRV7H0	Congestive heart failure	BD10	Approved	[6]
Ethacrynic acid	DM60QMR	Edema	MG29	Approved	[7]
Torasemide	DMXKJ6C	Congestive heart failure	BD10	Approved	[8]
Bendroflumethiazide	DM7EVLC	High blood pressure	BA00	Approved	[2]
Trichlormethiazide	DMHAQCO	Hypertension	BA00-BA04	Approved	[9]
Hydroflumethiazide	DMVPUQI	Congestive heart failure	BD10	Approved	[2]
Chlorthalidone	DM4DMBT	Edema	MG29	Approved	[10]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Solute carrier family 12 member 1 (SLC12A1)	TTS087L	S12A1_HUMAN	Blocker	[2]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7235).
• [2] DrugBank: a knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 2008 Jan;36(Database issue):D901-6.
• [3] Nongenomic effect of aldosterone on ion transport pathways of red blood cells. Cell Physiol Biochem. 2008;22(1-4):269-78.
• [4] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [5] Update of diuretics in the treatment of hypertension. Am J Ther. 2007 Mar-Apr;14(2):154-60.
• [6] Nerve Terminal GABAA Receptors Activate Ca2+/Calmodulin-dependent Signaling to Inhibit Voltage-gated Ca2+ Influx and Glutamate Release. J Biol Chem. 2009 Mar 27;284(13):8726-37.
• [7] Na-K-Cl cotransport regulates intracellular volume and monolayer permeability of trabecular meshwork cells. Am J Physiol. 1995 Apr;268(4 Pt 1):C1067-74.
• [8] Genetic variation in the renal sodium transporters NKCC2, NCC, and ENaC in relation to the effects of loop diuretic drugs. Clin Pharmacol Ther. 2007 Sep;82(3):300-9.
• [9] Function and regulation of epithelial sodium transporters in the kidney of a salt-sensitive hypertensive rat model. J Hypertens. 2007 May;25(5):1065-72.
• [10] The 45-year story of the development of an anti-aldosterone more specific than spironolactone. Mol Cell Endocrinol. 2004 Mar 31;217(1-2):45-52.